A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 06 Dec 2017 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Status changed from planning to not yet recruiting.
- 28 Apr 2017 According to a Sanofi media release, the company plans to initiate this trial in the third quarter of 2017.